Description: Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Home Page: www.astellas.com
2-5-1, Nihonbashi-Honcho
Tokyo,
103-8411
Japan
Phone:
81 3 3244 3000
Officers
| Name | Title |
|---|---|
| Mr. Naoki Okamura BSc | President, CEO & Director |
| Mr. Atsushi Kitamura | Senior Executive Officer & CFO |
| Nobue Yasuda | General Manager of Finance & Accounting Department |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer |
| Ms. Catherine B. Levitt J.D. | General Counsel |
| Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director |
| Mr. Stig Ogata | Vice President of Corporate Communications |
| Ms. Tatjana Dragovic | Senior VP and Head of Ethics & Compliance |
| Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive |
| Jun Kono | Senior Executive Officer & Head of Japan Commercial |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 12.3457 |
|---|---|
| Trailing PE: | 51.7684 |
| Price-to-Book MRQ: | 1.8298 |
| Price-to-Sales TTM: | 0.0102 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 14754 |